MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

AbbVie Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

205.82 -1.74

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

205.58

Max

211.94

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.6B

-23M

Pardavimai

642M

15B

P/E

Sektoriaus vid.

87.665

63.778

Pelnas, tenkantis vienai akcijai

2.16

Dividendų pajamingumas

3.13

Pelno marža

-0.152

Darbuotojai

55,000

EBITDA

-4.4B

535M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+4.51% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.13%

2.39%

Kitas uždarbis

2025-04-25

Kitas dividendų mokėjimo data

2025-05-15

Kita Ex Dividend data

2025-04-15

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

36B

371B

Ankstesnė atidarymo kaina

207.56

Ankstesnė uždarymo kaina

205.82

Naujienos nuotaikos

By Acuity

22%

78%

50 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

AbbVie Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-27 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility

2025-02-12 13:41; UTC

Pagrindinės rinkos jėgos

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

2025-01-31 13:28; UTC

Uždarbis

AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges

2025-03-14 09:30; UTC

Svarbiausios naujienos

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

2025-03-03 15:04; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

2025-02-28 12:00; UTC

Svarbiausios naujienos

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025-02-06 13:25; UTC

Svarbiausios naujienos
Uždarbis

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

2025-02-06 12:00; UTC

Uždarbis

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

2025-02-05 12:00; UTC

Svarbiausios naujienos

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

2025-01-31 15:50; UTC

Svarbiausios naujienos
Uždarbis

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

2025-01-31 13:51; UTC

Uždarbis

AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate -- IBD

2025-01-31 13:47; UTC

Svarbiausios naujienos
Uždarbis

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

2025-01-31 13:24; UTC

Rinkos pokalbiai
Uždarbis

AbbVie Gets More Upbeat on Skyrizi, Rinvoq -- Market Talk

2025-01-31 12:46; UTC

Uždarbis

AbbVie's Stock Pops 4% After Earnings Beat Estimates And Company Offers Upbeat View Of 2025 -- MarketWatch

2025-01-31 12:39; UTC

Uždarbis

AbbVie 4Q Global Rinvoq Net Revenue $1.83B, Up 46.2% >ABBV

2025-01-31 12:38; UTC

Uždarbis

AbbVie: Expect 2025 Revenue to Exceed Previous Peak >ABBV

2025-01-31 12:38; UTC

Uždarbis

AbbVie Now Sees Aesthetics Delivering High-Single-Digit Compound Annual Revenue Growth From 2025-2029 >ABBV

2025-01-31 12:37; UTC

Uždarbis

AbbVie Raises 2027 Combined Sales Outlook for Skyrizi, Rinvoq to More Than $31B >ABBV

2025-01-31 12:37; UTC

Uždarbis

AbbVie Reaffirms Expectations for High-Single-Digit Compound Annual Revenue Growth Rate Through 2029 >ABBV

2025-01-31 12:36; UTC

Uždarbis

AbbVie: 4Q Revenue Rose 6.1% on Operational Basis >ABBV

2025-01-31 12:36; UTC

Uždarbis

AbbVie 4Q Loss $22M >ABBV

2025-01-31 12:36; UTC

Uždarbis

AbbVie 4Q U.S. HUMIRA Rev $1.25B >ABBV

2025-01-31 12:36; UTC

Uždarbis

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.69B >ABBV

2025-01-31 12:36; UTC

Uždarbis

AbbVie 4Q Global Skyrizi Rev $3.78B >ABBV

2025-01-31 12:36; UTC

Uždarbis

AbbVie 4Q International HUMIRA Rev $436M >ABBV

2025-01-31 12:36; UTC

Uždarbis

AbbVie 4Q Adj EPS $2.16 >ABBV

2025-01-31 12:36; UTC

Uždarbis

AbbVie Sees FY Adj EPS $12.12-Adj EPS $12.32 >ABBV

2025-01-31 12:36; UTC

Uždarbis

AbbVie 4Q Loss/Shr 2c >ABBV

2025-01-31 12:36; UTC

Uždarbis

AbbVie 4Q Global IMBRUVICA Rev $848M >ABBV

2025-01-31 12:36; UTC

Uždarbis

AbbVie 4Q Rev $15.1B >ABBV

Akcijų palyginimas

Kainos pokytis

AbbVie Inc Prognozė

Kainos tikslas

By TipRanks

4.51% į viršų

12 mėnesių prognozė

Vidutinis 215.57 USD  4.51%

Aukščiausias 240 USD

Žemiausias 190 USD

Remiantis 16 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines AbbVie Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

16 ratings

12

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

201.34 / 210.78Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Rinkos nuotaikos

By Acuity

50 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.